Mayne Pharma Group Limited (ASX:MYX)

Revenue by Product

Financials in millions AUD. Fiscal year is July - June.

Year Ending	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017
Dermatology	174.86M
Dermatology Growth	206.81%
Womens Health	142.83M
Womens Health Growth	130.78%
International	70.71M
International Growth	9.29%

Revenue by Geography

Financials in millions AUD. Fiscal year is July - June.

Year Ending	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017
United States	322.13M
United States Growth	158.81%
Australia and New Zealand	40.34M
Australia and New Zealand Growth	-2.09%
Canada	13.37M
Canada Growth	34.62%
Europe and Other	7.13M
Europe and Other Growth	98.00%
Asia	5.44M
Asia Growth	23.78%